In a historic development for mental health care, Compass Pathways has successfully concluded its pivotal Phase 3 clinical trials for COMP360, a proprietary synthetic psilocybin therapy for treatment-resistant depression (TRD). The announcement, made earlier this week following the release of data from the COMP006 trial, positions the treatment for an imminent FDA review. With a rolling New Drug Application (NDA) expected to be completed by late 2026, millions of Americans suffering from depression could soon see the first ever psychedelic-assisted therapy approved for medical use.

Breaking News: COMP360 Clears Final Clinical Hurdles

On February 17, 2026, Compass Pathways confirmed that its second Phase 3 trial, COMP006, met its primary endpoint with high statistical significance. The study, which enrolled 581 participants across North America and Europe, demonstrated that two 25 mg doses of COMP360—administered three weeks apart in conjunction with psychological support—resulted in a 3.8-point greater reduction in depression symptoms compared to a control group.

This follows the success of the earlier COMP005 trial, which reported positive top-line results in mid-2025. Together, these trials provide the robust safety and efficacy data required by the FDA. "These data strengthen our conviction in the highly differentiated profile for COMP360," stated Kabir Nath, CEO of Compass Pathways. "We have now demonstrated consistent, highly statistically significant results... a remarkable achievement for the field of psychiatry."

Unprecedented Durability of Effect

One of the most promising findings from the Phase 3 program is the durability of the treatment. Data from the COMP005 trial revealed that a single administration of COMP360 maintained its therapeutic effect for at least 26 weeks in a significant portion of patients. In the more recent COMP006 trial, 39% of participants achieved a clinically meaningful reduction in symptom severity by Week 6.

Compass Pathways' Chief Medical Officer, Dr. Guy Goodwin, highlighted this durability as a key differentiator from existing treatments like Spravato (esketamine), which often requires weekly or bi-weekly clinic visits. "Evidence of durability is a key point for the FDA," Goodwin noted, adding that the company is providing this data "in spades."

The Path to FDA Approval in 2026

With the Phase 3 program complete, Compass Pathways is moving swiftly toward regulatory submission. The company has announced plans to initiate a rolling NDA submission to the U.S. Food and Drug Administration (FDA). This process allows the FDA to review completed sections of the application before the entire package is finalized, significantly speeding up the timeline.

The company expects to complete the full submission in the fourth quarter of 2026. Given that COMP360 has already received Breakthrough Therapy designation, the FDA's review process could be expedited. If the agency grants priority review, a final decision on approval could arrive as early as mid-2027, though the review process itself will define the regulatory landscape of 2026.

Why This Matters for Treatment-Resistant Depression

Treatment-resistant depression (TRD) affects an estimated 100 million people worldwide and nearly one-third of all patients diagnosed with major depressive disorder. These individuals have failed to respond to at least two standard antidepressant medications, leaving them with few options and a high burden of illness.

Traditional antidepressants, such as SSRIs, can take weeks to show effect and often come with chronic side effects like weight gain and sexual dysfunction. In contrast, psilocybin-assisted therapy offers a fundamentally different mechanism. It induces a rapid, temporary state of heightened neuroplasticity, allowing patients—with the guidance of a therapist—to disrupt rigid negative thought patterns.

"TRD patients have extremely limited treatment options, and the unmet need remains profound," said Dr. Steve Levine, Compass' Chief Patient Officer. The ability to achieve remission with just one or two doses could revolutionize how psychiatrists approach difficult-to-treat cases.

What Patients Can Expect Next

While the clinical trial results are a major victory, commercial availability is still several steps away. Following the completion of the NDA submission in late 2026, the FDA will conduct a rigorous review of the safety and efficacy data. The agency will also inspect manufacturing facilities and finalize the Risk Evaluation and Mitigation Strategy (REMS), which will dictate how the drug is administered.

Unlike a daily pill picked up at a pharmacy, COMP360 will likely be restricted to certified treatment centers where patients can be monitored by trained professionals during the 6-to-8-hour psychedelic session. Despite these logistical hurdles, the mood in the mental health community is optimistic. As Compass Pathways' stock surged nearly 33% following the news, it is clear that both investors and medical professionals see 2026 as the turning point for psychedelic medicine.